845673-97-4

Basic information

• Product Name: 5,6-DiHETE
• Synonyms: 5,6-DiHETE;5,6-DiHETE Exclusive;VPXVODYVPILPRC-LTKCOYKYSA-N
• CAS NO: 845673-97-4
• Molecular Formula: C₂₀H₃₂O₄
• Molecular Weight: 336.46568
• Mol File: 845673-97-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5,6-DiHETE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-DiHETE(845673-97-4)
• EPA Substance Registry System: 5,6-DiHETE(845673-97-4)

Safety Data

• Hazardous Substances Data: 845673-97-4(Hazardous Substances Data)

Usage

Description

5,6-DiHETE, also known as (±)5(6)-DiHETE, is a metabolite derived from the ω-3 polyunsaturated fatty acid Eicosapentaenoic acid (EPA). It is produced through the epoxidation of the α-5 double bond in EPA, followed by conversion to the vicinal diols by epoxide hydrolases. However, the biological activity of 5,6-DiHETE has not been documented.

Uses

Since the biological activity of 5,6-DiHETE has not been documented, there are no specific applications listed in the provided materials. Further research and documentation are required to determine its potential uses in various industries.

Upstream product

• 234087-56-0 6-[(3Z,6Z,9Z,12Z)-1-iodopentadeca-3,6,9,12-tetraen-1-yl]-tetrahydro-2H-pyran-2-one 
• 234087-57-1 Methyl (all-Z)-5,6-epoxyicosa-8,11,14,17-tetraenoate 

Relevant articles and documents

FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS

The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

Synthesis of docosahexaenoic acid derivatives designed as novel PPARγ agonists and antidiabetic agents

To discover novel peroxisome proliferator-activated receptor γ (PPARγ) agonists that could be used as antidiabetic agents, we designed docosahexaenoic acid (DHA) derivatives (2 and 3), which have a hydrophilic substituent at the C(4)-position, based on the crystal structure of the ligand-binding pocket of PPARγ. These compounds were synthesized via iodolactone as a key intermediate. We found that both DHA derivatives (2 and 3) showed PPARγ transactivation higher than, or comparable to, that of pioglitazone, which is a TZD derivative used as an antidiabetic agent. DHA derivatives related to these potent compounds 2 and 3 were also synthesized to study structure-activity relationships. Furthermore, 4-OH DHA 2, which shows strong PPARγ transcriptional activity, was separated as an optically pure form.